Successful conversion from cyclosporine to tacrolimus for immunosuppression.
Sekido
H
H
Department of Surgery II, Yokohama City University, School of Medicine, Yokohama, Japan.
Takeda
K
K
Morioka
D
D
Kubota
T
T
Togo
S
S
Nakatani
Y
Y
Matsunami
H
H
Lynch
S V
SV
Strong
R W
RW
Shimada
H
H
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001707:Biopsy, Needle; D056486:Chemical and Drug Induced Liver Injury / Q000473:pathology; D016572:Cyclosporine / Q000009:adverse effects* / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced / Q000188:drug therapy; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation; D007328:Insulin / Q000627:therapeutic use; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D009504:Neutrophils / Q000473:pathology; D016559:Tacrolimus / Q000627:therapeutic use*
D007166:Immunosuppressive Agents; D007328:Insulin; D016572:Cyclosporine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D016559:Tacrolimus